CAMBRIDGE, UK I November 11, 2024 I STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announces that it ...
NGGT has initiated Phase I/II clinical trials in the U.S. and China to evaluate the safety and efficacy of NGGT002 for the treatment of Phenylketonuria ...
TEZSPIRE demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo ...
CAMBRIDGE, MA, USA; ROTTERDAM, The Netherlands and SUZHOU, China I 8, 2024 I Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical ...
“Immunotherapy and personalized therapy has transformed cancer treatment. However, there is still a dire need for new innovative therapies. We believe that AM003 — as a new class of individualized ...
First-in-human randomized clinical trial demonstrates safety and tolerability of MD-18, Radella’s novel lead asset from its platform targeting cardiometabolic ...
PALO ALTO, CA, USA I November 07, 2024 I Pheast Therapeutics (“Pheast”), a biotech developing novel macrophage checkpoint therapies to defy cancer, today announced the presentation of new preclinical ...
REDMOND, WA, USA I November 8, 2024 I SystImmune, Inc (SystImmune), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational ...